<DOC>
	<DOCNO>NCT02812342</DOCNO>
	<brief_summary>The purpose study investigate use topical tofacitinib promote hair regrowth patient alopecia areata , alopecia totalis , alopecia universalis .</brief_summary>
	<brief_title>Topical Tofacitinib Treatment Alopecia Areata Its Variants</brief_title>
	<detailed_description>This open label clinical trial . We plan treat 10 adult AA ( least 2 patch alopecia involve scalp ) , AT AU tofacitinib ointment maximum 6 month . During treatment , patient evaluate every 4 week effectiveness medication measure change hair growth . Laboratory evaluation perform treatment order monitor adverse effect medication .</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Diagnosis AA least 2 patch alopecia involve scalp , AT AU Stable hair loss present 6 month longer No treatment alopecia areata past 1 month No evidence spontaneous hair regrowth Patients receive treatment know affect alopecia areata within 1 month enrol study Patients whose current episode AT AU 5 year Patients history malignancy ( except history successfully treat basal cell squamous cell carcinoma skin ) Patients known HIV hepatitis B C positive Patients positive tuberculin skin test positive QuantiFERON® TB test Patients leukopenia anemia Patients renal hepatic impairment Patients take immunosuppressive medication , include limited prednisone , methotrexate , mycophenolate mofetil , azathioprine , tacrolimus , cyclosporine , TNFα inhibitor Women pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Alopecia</keyword>
</DOC>